Breast cancer study highlights promising efficacy of T-DM1 after pertuzumab

Written by Heather Jones, Future Science Group

A study has found that patients with HER2-positive breast cancer, who have relapsed after initial combination therapy with pertuzumab, can respond well to T-DM1 as a second line treatment; demonstrating the value of continued anti-HER2 treatment. Bernedetta Conte, from the University of Genoa, Italy, is the first author of the study, which was published recently in Clinical Breast Cancer. Her team investigated the efficacy of T-DM1 as a second-line treatment in HER2-positive breast cancer patients. She presented the results at the Advanced Breast Cancer Fifth International Consensus Conference (14–16 November, Lisbon, Portugal). In this study, 77 eligible patients were identified....

To view the full article, please register now for access

It's completely free